Melola Discovery

← Melola Discovery

Journal SINTA 1

MCF-7 Resistant Doxorubicin are Characterized by Lamelapodia, Strong Adhesion on Substrate and P-gp Overexpression

Indonesian Journal of Cancer Chemoprevention · Vol. 2 No. 3 (2011) · pp. 304–309

DOI
10.14499/indonesianjcanchemoprev2iss3pp304-309
ISSN
2355-8989, 2088-0197
Published
2011-10-31
Publisher
Indonesian Society for Cancer Chemoprevention
Language
eng

Abstract

The prognosis of breast cancer patients is closely associated with the response of tumor cells to chemotherapy agent. Doxorubicin is one of the primary chemotherapeutic agents used for the treatment of breast cancer. Resistance to chemotherapy is believed to cause treatment failure in cancer patients. Furthermore, long time exposure to chemotherapeutic agent induces cancer cells resistance. MCF-7 sensitive cells used as chemoresistance model have overexpression P-gp (P-glycoprotein). Chemoresistance was established by treating MCF-7 cells with 0.5 µg/ml doxorubicin-contained medium for a week. 50% inhibiting concentration (IC50) doxorubicin on MCF-7 cells/DOX were determined using MTT assay. Western blot assay and immunocytochemistry assay was performed to determine the expression of P-gp. Morphological of MCF-7 cell/DOX was changing to become larger and have lamellapodia. IC50 value of doxorubicin was 700 nM on MCF-7/DOX and 400 nM on sensitive MCF-7 cells. The MCF-7/DOX sensitivity to doxorubicin was decreased, shown by 1.5 fold higher IC50 of doxorubicin on MCF-7/DOX compared to MCF-7 sensitive cells. Treatment doxorubicin to sensitive MCF-7 cells leads to the increasing P-gp expression. The P-gp level expression has strong correlation with the low sensitivity of MCF-7/DOX to doxorubicin.Keywords: doxorubicin, resistance cells, sensitive MCF-7 cell

Collaboration network of the authors

40 authors · 101 co-authorship links · 38 across different organisations · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Universitas Gadjah Mada
  • Muhammadiyah University of Yogyakarta
  • Jenderal Soedirman University
  • Universitas Jember
  • Sumatera Institute of Technology
  • Politeknik Kesehatan Bhakti Setya Indonesia
  • Universitas Airlangga
  • Other organisations
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Edy MeiyantoUniversitas Gadjah Mada9
Adam HermawanUniversitas Gadjah Mada5
Triana Arum KusumaningtyasMuhammadiyah University of Yogyakarta3
Erlina RivantiUniversitas Gadjah Mada3
Nur Amalia ChoironiJenderal Soedirman University3
Muthi IkawatiUniversitas Gadjah Mada3
Muhammad Salman FarezaJenderal Soedirman University2
Banun KusumawardaniUniversitas Jember2
Nuha Haifa ArifinMuhammadiyah University of Yogyakarta2
Melisa JunianandaMuhammadiyah University of Yogyakarta2
Dhecella Winy Cintya NingrumMuhammadiyah University of Yogyakarta2
Nisa Yulianti SuprahmanSumatera Institute of Technology2
Muhamad Salman FarezaJenderal Soedirman University2
Ivana Kinanti KenyoriMuhammadiyah University of Yogyakarta2
Anindyajati AnindyajatiUniversitas Gadjah Mada2
Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Indonesia Department of PharmacyAffiliation unknown1
Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto, Indonesia Department of PharmacyAffiliation unknown1
Jenderal Soedirman University, Purwokerto 53123, Indonesia Department of PharmacyAffiliation unknown1
Raymond DevaraJenderal Soedirman University1
Dwi Merry Christmarini RobinUniversitas Gadjah Mada1
Irma Josefina SavitriUniversitas Airlangga1
Dea Ajeng Pravita SuendiUniversitas Jember1
Rawi Ingra SavitriMuhammadiyah University of Yogyakarta1
Diyah Novi SekariniUniversitas Gadjah Mada1
Yohanes Surya JatiUniversitas Gadjah Mada1
Nur Ayunie ZulkepliUniversiti Teknologi MARA1
Adi HermawansyahMuhammadiyah University of Yogyakarta1
Chaessy Yori AnggrainiMuhammadiyah University of Yogyakarta1
Aji WinantaMuhammadiyah University of Yogyakarta1
Linta Sabila HanikMuhammadiyah University of Yogyakarta1
Sugeng RiyantoUniversitas Gadjah Mada1
Endah Dwi SetyowatiRumah Sakit Umum Pusat Dr. Sardjito1
Binar Asrining DhianiMuhammadiyah University Purwokerto1
Etyk Yunita AnjarsariUniversitas Gadjah Mada1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OAI-PMH (metadata jurnal) https://ijcc.chemoprev.org/index.php/ijcc/oai, first harvested 8 Nov 2026, last seen 8 Nov 2026.
Original metadata (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">MCF-7 Resistant Doxorubicin are Characterized by Lamelapodia, Strong Adhesion on Substrate and P-gp Overexpression</dc:title>
	<dc:creator>Putri, Dyaningtyas Dewi Pamungkas</dc:creator>
	<dc:creator>Sarmoko, Sarmoko</dc:creator>
	<dc:creator>Febriansah, Rifki</dc:creator>
	<dc:creator>Puspitasari, Endah</dc:creator>
	<dc:creator>Ismiyati, Nur</dc:creator>
	<dc:creator>Fitriasari, Aditya</dc:creator>
	<dc:description xml:lang="en-US">The prognosis of breast cancer patients is closely associated with the response of tumor cells to chemotherapy agent. Doxorubicin is one of the primary chemotherapeutic agents used for the treatment of breast cancer. Resistance to chemotherapy is believed to cause treatment failure in cancer patients. Furthermore, long time exposure to chemotherapeutic agent induces cancer cells resistance. MCF-7 sensitive cells used as chemoresistance model have overexpression P-gp (P-glycoprotein). Chemoresistance was established by treating MCF-7 cells with 0.5 µg/ml doxorubicin-contained medium for a week. 50% inhibiting concentration (IC50) doxorubicin on MCF-7 cells/DOX were determined using MTT assay. Western blot assay and immunocytochemistry assay was performed to determine the expression of P-gp. Morphological of MCF-7 cell/DOX was changing to become larger and have lamellapodia. IC50 value of doxorubicin was 700 nM on MCF-7/DOX and 400 nM on sensitive MCF-7 cells. The MCF-7/DOX sensitivity to doxorubicin was decreased, shown by 1.5 fold higher IC50 of doxorubicin on MCF-7/DOX compared to MCF-7 sensitive cells. Treatment doxorubicin to sensitive MCF-7 cells leads to the increasing P-gp expression. The P-gp level expression has strong correlation with the low sensitivity of MCF-7/DOX to doxorubicin.Keywords: doxorubicin, resistance cells, sensitive MCF-7 cell</dc:description>
	<dc:publisher xml:lang="en-US">Indonesian Society for Cancer Chemoprevention</dc:publisher>
	<dc:contributor xml:lang="en-US"></dc:contributor>
	<dc:date>2011-10-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijcc.chemoprev.org/index.php/ijcc/article/view/48</dc:identifier>
	<dc:identifier>10.14499/indonesianjcanchemoprev2iss3pp304-309</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Cancer Chemoprevention; Vol 2, No 3 (2011); 304-309</dc:source>
	<dc:source>2355-8989</dc:source>
	<dc:source>2088-0197</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/view/48/49</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2017 Indonesian Journal of Cancer Chemoprevention</dc:rights>
</oai_dc:dc>